Journal Article DZNE-2026-00371

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Protocol of a dyadic, app-supported collaborative care intervention trial for informal caregivers of people living with dementia-the multi-center living@home study.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
BioMed Central London

Trials 27(1), 284 () [10.1186/s13063-026-09639-x]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Informal caregivers provide a large part of the care required by people living with dementia. With disease progression, the burden on caregivers typically increases. Dyadic interventions, addressing both the caregiver and the person living with dementia simultaneously, can help to stabilize home care settings. This study examines the effectiveness and cost-effectiveness of an app-assisted dementia care intervention.Living@home is a two-arm, randomized, controlled, multi-center interventional study designed to evaluate the effectiveness of a dyadic, app-based intervention on home care stability as well as the cost-effectiveness of this approach. The inclusion criteria are a formal diagnosis of dementia and living in their own home for the person with dementia, as well as access to a smartphone and internet for the informal caregiver. A total of 554 dyads will be recruited in five participating memory clinics and randomized (1:1 ratio, using block randomization) into either the intervention or the control group. The intervention group will receive personalized dementia care management for a period of 12 months. A mobile health app connecting caregivers with a Family Care Specialist offers informal caregivers access to memory clinics and Care Specialists at any time, monitoring of their health situation through real-time data collection, overview of care-related tasks, information and alerts tailored to the reported individual caregiver burden. The control group receives care-as-usual. Both groups will be assessed at baseline and after 12 months. The primary outcome is the caregiver's perseverance time (Perseverance Time Scale), and crucial secondary supportive outcomes are neuropsychiatric symptoms in the person living with dementia (Neuropsychiatric Inventory), and the caregiver's perceived burden (Zarit Burden Interview). Further secondary outcomes include the caregiver's resilience and self-efficacy, the dyads' physiological stress level (as measured by hair cortisol concentrations), health-related quality of life, caregiver depression and anxiety, dyads' unmet needs, and cost-effectiveness. Intervention effects will be estimated by using multivariate regression analyses.Evidence on the effectiveness and cost-effectiveness of the intervention created from this study can help to inform decision makers and support the transition of the intervention to standard care.ClinicalTrials.gov NCT07251088, Registered 25.11.2025.

Keyword(s): Humans (MeSH) ; Caregivers: psychology (MeSH) ; Caregivers: economics (MeSH) ; Dementia: therapy (MeSH) ; Dementia: psychology (MeSH) ; Dementia: diagnosis (MeSH) ; Dementia: economics (MeSH) ; Mobile Applications: economics (MeSH) ; Multicenter Studies as Topic (MeSH) ; Cost-Benefit Analysis (MeSH) ; Randomized Controlled Trials as Topic (MeSH) ; Quality of Life (MeSH) ; Telemedicine: economics (MeSH) ; Time Factors (MeSH) ; Home Care Services: economics (MeSH) ; Caregiver Burden: psychology (MeSH) ; Caregiver burden ; Collaborative care ; Dementia ; Dementia care management ; Informal caregivers ; MHealth app ; Mobile app ; Randomized controlled trial

Classification:

Contributing Institute(s):
  1. Patient-Reported Outcomes and Health Economics Research (AG Michalowsky)
  2. Translational Health Care Research (AG Hoffmann)
  3. Interventional Health Care Research (IHCR) (AG Thyrian)
  4. Care Structures (AG Holle)
  5. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
  6. Epigenetics and Systems Medicine in Neurodegenerative Diseases (AG Fischer)
  7. Molecular biomarkers for predictive diagnostics of neurodegenerative diseases (AG Wiltfang)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
  2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2026
Database coverage:
Medline ; Creative Commons Attribution CC BY 4.0 ; DOAJ ; OpenAccess ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > ROS DZNE > ROS DZNE-AG Hoffmann
Institute Collections > GÖ DZNE > GÖ DZNE-AG Wiltfang
Institute Collections > ROS DZNE > ROS DZNE-AG Thyrian
Institute Collections > GÖ DZNE > GÖ DZNE-AG Fischer
Institute Collections > ROS DZNE > ROS DZNE-AG Teipel
Institute Collections > WIT DZNE > WIT DZNE-AG Holle
ROS DZNE-AG Michalowsky
Full Text Collection
Public records
Publications Database

 Record created 2026-04-13, last modified 2026-04-21


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)